SFX by Ex Libris Inc.

Title:	Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis
Source:	Genes and Immunity [1466-4879] Zhang, Z yr:2005

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Okamura, T. "Roles of LAG3 and EGR2 in regulatory T cells." Annals of the rheumatic diseases 71 (2012): 96-100.
description	2.	Zhu, X. "CD4࠽맹㫞 express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation." Graefe's Archive for Clinical and Experimental Ophthalmology 245.10 (2007): 1549-1557.
description	3.	Bielekova, B. "Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7." Journal of neuroimmunology 100.1-2 (1999): 115-23.
description	4.	Guo, H. "Inflammasomes: mechanism of action, role in disease, and therapeutics." Nature medicine 21.7 (2015): 677-87.
description	5.	Leist, H F. "VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis." Journal of neuroimmunology 111.1-2 (2000): 186-194.
description	6.	Jegaskanda, S. "Comparison of Influenza and SIV Specific CD8 T Cell Responses in Macaques." PLoS ONE 7.3 (2012).
description	7.	Curran, Michael A. "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors." Proceedings of the National Academy of Sciences of the United States of America 107.9 (2010): 4275-4280.
description	8.	Han, Y. "Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma." Leukemia 20.9 (2006): 1602-9.
description	9.	Huang, Ching-Tai T. "Role of LAG-3 in regulatory T cells." Immunity 21.4 (2004): 503-13.
description	10.	Safford, M. "Egr-2 and Egr-3 are negative regulators of T cell activation." Nature immunology 6.5 (2005): 472-80.
description	11.	Coll, Rebecca C. "A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases." Nature medicine 21.3 (2015): 248-55.
description	12.	Huard, B. "Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes." European journal of immunology 24.12 (1995): 3216-21.
description	13.	Broderick, L. "The inflammasomes and autoinflammatory syndromes." Annual review of pathology 10.1 (2015): 395-424.
description	14.	McAllen, D M. "The cholinergic anti-inflammatory pathway: A critical review." Autonomic neuroscience: basic & clinical 182 (2013): 65-69.
description	15.	Sadelain, M. "PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses." Science translational medicine 5.215 (2013): 215-215.
description	16.	Duraiswamy, J. "Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors." Cancer research 73.12 (2013): 3591-3603.
description	17.	Curran, Michael A. "Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production." PLoS ONE 6.4 (2011).
description	18.	"Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques." Journal of virology : JVI. 83.15: 7619-7628.
description	19.	Perry, Justin S A S. "Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis." Science translational medicine 4.145 (2012): 145-145.
description	20.	Arlehamn, Cecilia S Lindestam S. "Dissecting Mechanisms of Immunodominance to the Common Tuberculosis Antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ)." The journal of immunology 188.10 (2012): 5020-5031.